Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
9
Mins
31st May 2016
Non-Malignant Portal Vein Thrombosis in Liver Cirrhosis: Diagnosis and Treatment
Portal vein thrombosis (PVT) is considered a common complication of liver cirrhosis. Its prevalence increases with liver disease severity, reaching 25%…
25th May 2016
KEYNOTE-010: Pembrolizumab versus docetaxel in advanced PD-L1-positive NSCLC
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
25th May 2016
ASCEND-2 and ASCEND-3 trials: Ceritinib in ALK-rearranged NSCLC with brain metastases
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
25th May 2016
Immune checkpoint inhibitors, durvalumab plus tremelimumab, for non-small cell lung cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Solange Peters, MD, PhD…
25th May 2016
Immunotherapy for hepatocellular carcinoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Su Pin Choo, MBBS…
25th May 2016
Phase 3 LUX-H&N1 trial: Afatinib versus methotrexate for head and neck squamous cell carcinoma
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Makoto Tahara, MD…
25th May 2016
Endocrine therapy in pregnant women with breast cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
25th May 2016
Olaparib and bevacizumab: On the horizon for treating ovarian cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS…
25th May 2016
Tumour biomarker changes after neoadjuvant chemotherapy in breast cancer
At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Sibylle Loibl, MD, PhD…
25th May 2016
From biologics to biosimilars
A biosimilar can be defined as a biological product that demonstrates no clinically meaningful differences to an approved biological product. At the…
←
1
2
3
…
747
748
749
750
751
752
753
…
866
867
868
→